In this Yr16 renewal of our longitudinal study on the natural progression of AD biomarkers, the central goal remains to further understand the occurrence of asymptomatic amyloid-beta (A?) and tau deposition and the progression to clinical cognitive impairment. This cohort has now matured to the point that there is now sufficient longitudinal follow-up to address important hypotheses that were formulated from the beginning of this study but could not be properly addressed until 10-15 years of follow-up were in place - as is the case now. In this renewal period we aim to better characterize the different roles gray matter brain aging and small vessel disease have on AD progression. Chronological age is the most salient risk factor for late-onset AD. However, it remains unclear what components of the aging process account for this risk. In this proposal, we use gray matter brain age models to study the atrophy-related components of aging and 7T vascular imaging to characterize the SVD components of aging.
Aim 1 uses this estimated gray matter brain age to explain individual differences in AD biomarkers and cognitive decline.
Aim 2 uses fMRI and cerebrovascular imaging at 7T to examine the role of SVD in accelerating the amyloid-induced tauopathy and neurodegeneration.
Aim 3 ties together brain aging and SVD to test components of a model that small vessel disease (SVD) accelerates Tau deposition and neurodegeneration (including accelerated gray matter brain aging). Over the last 2 years we have transitioned the MR imaging of this study to a 7T MR scanner to take advantage of its high field strength for 1) characterizing small vessel morphology (e.g., early markers of cerebrovascular disease) associated with AD risk and 2) characterizing functional neural systems (fMRI). Over the course of this study we have shown that many (~25%) of cognitively unimpaired older adults have significant cerebral amyloid deposition, subsequently defined as preclinical AD. We and others have shown that in this preclinical stage, cross-sectional Ab burden is only weakly associated with objective cognitive performance. At this early disease stage, Ab burden is more strongly associated with changes in the functional connectivity, which can be measured by fMRI. We and others have identified that regional medial temporal lobe functional connectivity (MTL_FC) during memory encoding is associated with increased Ab load. In recent preliminary work, we have found that traditional markers of SVD interact with amyloid burden in their relationship to MTL_FC. Those with high Ab and high White Matter Hyperintensity (WMH) burden have particularly high regional MTL_FC. In individuals with Ab burden, SVD accelerates tau deposition, neurodegeneration, and progression of cognitive and clinical decline. The current cohort of 70 active participants will be supplemented by recruitment of additional older adults to achieve 200 baseline assessments. Individuals will undergo 3 MRI scans and 2 Ab- and tau-PET scans over a 32-month interval.

Public Health Relevance

This study was one of the first to demonstrate that cerebral amyloid deposition precedes cognitive decline by as much as 10-15 years. There appears to be great variability in the time from becoming amyloid positive until cognitive decline. Longitudinal studies, such as this one, which has been going on for 15 years, provide a unique opportunity to characterize the progression to Alzheimer?s disease.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Multi-Year Funded Research Project Grant (RF1)
Project #
Application #
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Wagster, Molly V
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Wilckens, Kristine A; Tudorascu, Dana L; Snitz, Beth E et al. (2018) Sleep moderates the relationship between amyloid beta and memory recall. Neurobiol Aging 71:142-148
Minhas, Davneet S; Price, Julie C; Laymon, Charles M et al. (2018) Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A? load. Neuroimage Clin 19:182-189
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750
Nadkarni, Neelesh K; Lopez, Oscar L; Perera, Subashan et al. (2017) Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. J Gerontol A Biol Sci Med Sci 72:431-437
Edelman, Kathryn; Tudorascu, Dana; Agudelo, Christian et al. (2017) Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. Am J Geriatr Psychiatry 25:551-560
Mathis, Chester A; Lopresti, Brian J; Ikonomovic, Milos D et al. (2017) Small-molecule PET Tracers for Imaging Proteinopathies. Semin Nucl Med 47:553-575
Goodheart, A E; Tamburo, E; Minhas, D et al. (2015) Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. Neuroimage Clin 9:479-83

Showing the most recent 10 out of 69 publications